Posted by Michael Wonder on 30 Dec 2020
Eyenovia submits new drug application to FDA for pharmacologic mydriasis with MydCombi targeting 80 million patient encounters in the U.S. annually
29 December 2020 - Eyenovia today announced that it has submitted a new drug application to the U. S. FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent.
If approved, MydCombi would be the first micro-dosed ocular therapeutic with a high precision smart delivery system.
